Shandong Xinhua Pharmaceutical Co., Ltd

Hualu Network Group 中文版

Investor Relation

Information transparency and trust in peers

Investor Relation

INTERIM REPORT

Overseas Regulatory Announcement-Announcement on the Ibuprofen Granules of Subsidiary Having Obtained the Drug Registration Certificate

Overseas Regulatory Announcement-Announcement In Relation to Obtaining of the Notification of Approval of Supplementary Drug Application and Other Relevant Information

Announcement Notice of Board Meeting

Overseas Regulatory Announcement-Announcement on Entacapone Tablets having obtained the Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Saxagliptin and Metformin Hydrochloride Sustained-release Tablets of Subsidiary Having Obtained the Drug Registration Certificate

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2026

Overseas Regulatory Announcement-Announcement on Glucosamine Sulfate Capsules for Suspension having obtained the Drug Registration Certificate

The Termination of the Equity Acquisition Intention Agreement

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2026

Next Day Disclosure Returns

总条数: 79条

＜ 1 2 3 4 ... 8 ＞

跳转到: 页